Calcium regulates the expression of insulin-like growth factor binding protein-3 by the human keratinocyte cell line HaCaT.
The insulin-like growth factor (IGF) system is essential for epidermal homeostasis. Insulin-like growth factor binding protein 3 (IGFBP-3), a modulator of IGF action that also exhibits IGF-independent activity, is localized to selected keratinocytes in the basal epidermal layer and may thus contribute to keratinocyte differentiation. We have utilized the human keratinocyte cell line, HaCaT, to examine the effect of calcium on the regulation of components of the IGF system. Western ligand and northern blot analyses revealed secreted IGFBP-3 and IGFBP-3 mRNA were reduced by an elevation in calcium levels in the culture medium. At 1.0 and 1.2 mM CaCl2 culture conditions IGFBP-3 abundance was reduced to 36% +/- 1.6% and 26% +/- 7.1%, respectively, of that from cells grown at 0.03 mM CaCl2. IGFBP-3 mRNA levels in 0.7 mM and 1.2 mM CaCl2 were reduced to 46% +/- 17.4% and 24% +/- 4.6%, respectively, compared with IGFBP-3 mRNA levels at 0.03 mM CaCl2. The observed reduction of IGFBP-3 was not associated with IGFBP-3 proteolysis. In contrast IGF-I receptor protein and mRNA levels remained unchanged. The IGF-I stimulated proliferative response of HaCaT keratinocytes showed that under low (0.03 mM) and high (1.2 mM) CaCl2 conditions IGF-I at 100 and 1000 ng per ml similarly increased cell number 2.4- and 2.7-fold, respectively, with similar dose-response curves. HaCaT keratinocytes grown under medium (0.7 mM) and high (1.2 mM), but not low (0.03 mM), CaCl2 conditions for 21 d revealed an induction of profilaggrin mRNA, a marker of keratinocyte differentiation. These studies indicate that the exposure of HaCaT keratinocytes to elevated calcium levels is associated with a decline in IGFBP-3 but not IGF-I receptor levels. These findings suggest a potential mechanism for the distribution of IGFBP-3 in the epidermis, which may be involved in the process of keratinocyte differentiation.
Edmondson
S R
SR
Center for Hormone Research, Murdoch Childrens Research Institute, Parkville, Victoria, Australia. edmondss@cryptic.rch.unimelb.edu.au
Werther
G A
GA
Wraight
C J
CJ
D002118:Calcium / Q000378:metabolism / Q000494:pharmacology / Q000502:physiology*; D002455:Cell Division / Q000187:drug effects; D002460:Cell Line; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D010450:Endopeptidases / Q000378:metabolism; D004790:Enzyme Induction / Q000502:physiology; D000091344:Filaggrin Proteins; D006801:Humans; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000235:genetics / Q000378:metabolism*; D007334:Insulin-Like Growth Factor I / Q000494:pharmacology; D007381:Intermediate Filament Proteins / Q000235:genetics; D015603:Keratinocytes / Q000187:drug effects / Q000378:metabolism*; D011498:Protein Precursors / Q000235:genetics; D012333:RNA, Messenger / Q000378:metabolism; D017526:Receptor, IGF Type 1 / Q000235:genetics / Q000378:metabolism / Q000502:physiology
D000091344:Filaggrin Proteins; D018972:Insulin-Like Growth Factor Binding Protein 3; D007381:Intermediate Filament Proteins; D011498:Protein Precursors; D012333:RNA, Messenger; D007334:Insulin-Like Growth Factor I; D017526:Receptor, IGF Type 1; D010450:Endopeptidases; D002118:Calcium